Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, randomised, open label, multicentre Phase II clinical trial to investigate the efficacy and safety of the treatment of large defects (4-10 cm2) with 3 different doses of the autologous chondrocyte transplantation product co.don chondrosphere (ACT3D-CS) in subjects with cartilage defects of the knee

Next Previous
X
Search
Trial Profile

Prospective, randomised, open label, multicentre Phase II clinical trial to investigate the efficacy and safety of the treatment of large defects (4-10 cm2) with 3 different doses of the autologous chondrocyte transplantation product co.don chondrosphere (ACT3D-CS) in subjects with cartilage defects of the knee

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous cultured chondrocytes (Primary)
  • Indications Knee injuries
  • Focus Registrational; Therapeutic Use
  • Sponsors co.don AG

    • Most Recent Events

    • 01 Dec 2023 According to a ReLive Biotechnologies media release, the company has received New Drug Application (NDA) approval for SpheChon 10-70 spheroids/cm2 in December 2023 by the Health Sciences Authority (HSA), Singapore.
    • 16 Apr 2018 New trial record
    • 05 Apr 2018 According to the co.don AG media release, interim results collected annually over the four-year follow-up period and five-year follow-up examination was carried out for the last patient in early 2018, which was followed by final statistical analysis and evaluation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top